678 related articles for article (PubMed ID: 34019934)
1. AGE/RAGE in diabetic kidney disease and ageing kidney.
Wu XQ; Zhang DD; Wang YN; Tan YQ; Yu XY; Zhao YY
Free Radic Biol Med; 2021 Aug; 171():260-271. PubMed ID: 34019934
[TBL] [Abstract][Full Text] [Related]
2. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
3. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.
Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG
Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680
[TBL] [Abstract][Full Text] [Related]
5. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
6. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.
Khalid M; Petroianu G; Adem A
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131
[TBL] [Abstract][Full Text] [Related]
7. DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice.
Sotokawauchi A; Matsui T; Higashimoto Y; Nishino Y; Koga Y; Yagi M; Yamagishi SI
Diab Vasc Dis Res; 2021; 18(1):1479164121990533. PubMed ID: 33535822
[TBL] [Abstract][Full Text] [Related]
8. Vaccination Against Receptor for Advanced Glycation End Products Attenuates the Progression of Diabetic Kidney Disease.
Azegami T; Nakayama T; Hayashi K; Hishikawa A; Yoshimoto N; Nakamichi R; Itoh H
Diabetes; 2021 Sep; 70(9):2147-2158. PubMed ID: 34155040
[TBL] [Abstract][Full Text] [Related]
9. Dicarbonyl-mediated AGEing and diabetic kidney disease.
Dimitropoulos A; Rosado CJ; Thomas MC
J Nephrol; 2020 Oct; 33(5):909-915. PubMed ID: 32170575
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice.
Lin CP; Huang PH; Chen CY; Wu MY; Chen JS; Chen JW; Lin SJ
Sci Rep; 2021 Sep; 11(1):17851. PubMed ID: 34497344
[TBL] [Abstract][Full Text] [Related]
11. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
[TBL] [Abstract][Full Text] [Related]
12. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products in the pathogenesis of chronic kidney disease.
Rabbani N; Thornalley PJ
Kidney Int; 2018 Apr; 93(4):803-813. PubMed ID: 29477239
[TBL] [Abstract][Full Text] [Related]
14. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging.
Teissier T; Boulanger É
Biogerontology; 2019 Jun; 20(3):279-301. PubMed ID: 30968282
[TBL] [Abstract][Full Text] [Related]
15. AKF-PD alleviates diabetic nephropathy via blocking the RAGE/AGEs/NOX and PKC/NOX Pathways.
Qin J; Peng Z; Yuan Q; Li Q; Peng Y; Wen R; Hu Z; Liu J; Xia X; Deng H; Xiong X; Hu J; Tao L
Sci Rep; 2019 Mar; 9(1):4407. PubMed ID: 30867431
[TBL] [Abstract][Full Text] [Related]
16. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
17. Pinocembrin Protects from AGE-Induced Cytotoxicity and Inhibits Non-Enzymatic Glycation in Human Insulin.
Borriello M; Iannuzzi C; Sirangelo I
Cells; 2019 Apr; 8(5):. PubMed ID: 31035509
[TBL] [Abstract][Full Text] [Related]
18. A Perspective on the Impact of Advanced Glycation End Products in the Progression of Diabetic Nephropathy.
Khanam A; Ahmad S; Husain A
Curr Protein Pept Sci; 2023; 24(1):2-6. PubMed ID: 36366848
[TBL] [Abstract][Full Text] [Related]
19. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products and insulin resistance.
Unoki H; Yamagishi S
Curr Pharm Des; 2008; 14(10):987-9. PubMed ID: 18473850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
